D&D Pharmaceuticals, a South Korean clinical-stage biopharmaceutical company focused on developing medicines for metabolic, fibrotic, and neurodegenerative diseases, has recently…
Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded…
Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET…
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a…
At this year’s American Diabetes Association (ADA) congress, while obesity and diabetes treatments took the limelight, there were sessions focused…
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While…
Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s…
Eli Lilly’s Foundayo (orforglipron) has led to weight loss of 13% in post-hoc analysis of patients aged over 65 from…
The European Congress on Obesity (ECO) 2026 has historically focused primarily on weight reduction. However, this year, a shift in…
Fractyl Health’s trial to evaluate a glucagon-like peptide-1 (GLP-1) gene therapy has been approved by European authorities. The open-label, first-in-human,…
